The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Selected safety information,
including boxed warning on use
in pregnancy.
Merck
COZAAR® (losartan potassium tablets) & HYZAAR® (losartan potassium-hydrochlorothiazide tablets)

Resources

Video Presentations
View expert audio and video presentations about hypertension treatment strategies.
Related Links
Get instant access to a variety of professional associations, journals, practice guidelines, and research organizations.

OTHER RESOURCES ON THIS SITE

Prescription Assistance
Direct your patients to resources that help them afford their medicines, either through discounts or assistance programs.
Coverage & Availability
Access the status of COZAAR on selected formularies.
USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, COZAAR and HYZAAR should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

Before prescribing COZAAR and HYZAAR, please read the Prescribing Information and Patient Information.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
COZAAR and HYZAAR are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Delaware, USA.
20851323(3)-07/08-COZ
SITE MAPPRIVACY POLICYTERMS OF USECOPYRIGHT © 1995-2008 MERCK & CO., INC.MERCK & CO., INC. (USA)